A

Amgen

Makes biotech medicines for serious illnesses

Engineer – Drug Substance Technology & Engineering

Full-TimeUpdated on 10/24/2026
$88.3k - $119.4k+ Discretionary annual bonus + Stock-based long-term incentives
Mid
Bachelor's, Master's
Thousand Oaks, CA, USA
In PersonOnsite role at the Thousand Oaks, California site.
Biology & BiotechBioprocess & Biomanufacturing
H1B Sponsorship Available

About the job

Requirements
  • A master's degree, or a bachelor's degree and 2 years of Process Development experience, or an associate's degree and 6 years of Process Development experience, or a high school diploma/GED and 8 years of Process Development experience.
  • 3+ years of experience in Process Engineering related to biochemical engineering and/or protein biochemistry, scale-up principles, and biologics manufacturing in a cGMP environment.
  • Downstream process knowledge and hands-on purification pilot, clinical, or commercial experience in biological drug substance manufacturing.
  • Experience working in or supporting a commercial cGMP manufacturing facility.
  • A firm understanding of purification processes and related equipment, including scale-up from bench to commercial scale, chromatography, viral inactivation, viral filtration, ultrafiltration and diafiltration, and the impact of process deviations on yield and quality attributes.
  • Knowledge of aseptic processing and techniques, harvest and clarification processes used in mammalian cell culture processes, and/or a good understanding of purification processes and associated equipment, including chromatography, ultrafiltration, normal flow filtration, virus inactivation, and virus filtration operations.
  • Process Development experience supporting cGMP manufacturing at large scale.
  • Capability in scientific, engineering, and laboratory analysis; troubleshooting; and sophisticated problem resolution.
  • Ability to develop and follow detailed protocols.
  • Ability to multitask and work in teams.
  • Written and verbal communication skills, including technical writing and presentations.
Responsibilities
  • Transfer purification drug substance processes and process improvements from the laboratory to manufacturing facilities and between manufacturing sites.
  • Provide solutions to technical problems of moderate scope and complexity.
  • Evaluate, select, and apply standard engineering techniques and procedures under general supervision, seeking assistance when addressing unusual problems.
  • Support process validation for late-stage commercial processes.
  • Provide on-the-floor technical support for process scale-up and technology transfer, as well as clinical and commercial manufacturing operations.
  • Perform routine and nonroutine process monitoring and troubleshooting.
  • Support nonstandard shift schedules and extended hours as business needs require.
  • Trend process data and perform statistical analyses.
  • Provide technical input for process-related deviations, nonconformances, corrective and preventive actions, and change controls.
  • Identify and support process-related operational excellence and continuous improvement opportunities, including efforts to improve efficiency across business process workstreams.
  • Represent Process Development and collaborate with Manufacturing, Quality, Regulatory, Research, Maintenance, Utilities, Facilities, and Validation teams to develop requirements and recommendations for process or system modifications.
  • Communicate and collaborate with technical and management staff across Manufacturing, Process Development, and Quality.
  • Complete assignments with clear objectives that require investigating a limited number of variables.
  • Serve as a technical expert for equipment and systems troubleshooting, becoming actively involved in daily operations as needed to meet schedules or resolve complex problems.
  • Apply engineering principles and statistical methods, including design of experiments, to resolve processing issues and evaluate process improvement opportunities.
Desired Qualifications
  • A master's degree in Chemical Engineering, Biochemical Engineering, or a related subject area.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

PR Newswire
Oct 26th, 2026
Amgen appoints former Yum! Brands CEO David Gibbs to its board

Amgen has appointed David W. Gibbs to its board of directors, effective immediately. He will serve on the Audit Committee and the Compensation and Management Development Committee. Gibbs recently retired as president and chief executive officer of Yum! Brands, owner of Taco Bell and Kentucky Fried Chicken. As chief executive from 2020 to 2025, he led its digital transformation and expanded it to nearly 61,000 locations. He has sat on the board of Under Armour since 2021 and PepsiCo since 2026. "His experience creating direct relationships with customers will help inform how we prepare for future launches," said Robert A. Bradway, Amgen's chairman and chief executive officer. The board now has 13 directors, 12 of them independent.

Yahoo Finance
Oct 26th, 2026
ESMO 2026: Moderna vaccine debate, Roche's $3.6B KRAS bet and Amgen's lung cancer data

Three cancer drug trials drew attention at the European Society for Medical Oncology (ESMO) meeting, with investors and analysts weighing the results. Moderna and Merck's vaccine intismeran autogene cut the relative risk of melanoma recurrence or death by 42% in a Phase 3 trial. Moderna's shares have still fallen by double digits since the results leaked early, as investors question its valuation and the vaccine's manufacturing and commercial potential. Roche's divarasib reduced the risk of death or disease progression by 42% in KRAS G12C lung cancer, beating Krazati and Lumakras. Patients lived a median of about 18 months, versus a year. Roche raised its peak sales forecast from 3.6 billion Swiss francs to 3 billion. Amgen's Imdelltra, combined with Imfinzi, cut the risk of death by 58% in small cell lung cancer. Median survival was 21.1 months, against 12.7 months for Imfinzi alone.

Yahoo Finance
Oct 25th, 2026
Amgen vs Gilead: Which biotech dividend stock is the better buy, with yields of 2.2% and 2.1%?

Amgen and Gilead Sciences, two of the few big biotech companies that pay dividends, suit different kinds of income investors, according to a comparison by The Motley Fool's Keith Speights. Amgen offers a forward dividend yield above 2.2%, against slightly below 2.1% for Gilead. Gilead has the lower payout ratio, at 43.5% versus 60.9%, and the cheaper valuation: 15.6 times forward earnings against 16.7. Amgen's product sales grew 9% year over year in its latest quarter, against 8% for Gilead. It has 17 drugs on track to be blockbusters this year, versus eight for Gilead, and 29 late-stage programs. Speights favours Amgen for yield and growth, and Gilead for safety and value.

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.